Study Protocol Systematic Review

Impact of full field digital mammography diagnosis for female patients with breast cancer

Tuan Wang, MMD, Jian-jun Shuai, MB, Xing Li, MB, Zhi Wen, MB*

Abstract

Background: Previous clinical studies have reported that full field digital mammography (FFDM) can be used for diagnosis on breast cancer (BC) with promising outcome results. However, no study systematically investigates its diagnostic impact on female patients with BC. Thus, this systematic review will assess the accurate of FFDM diagnosis on BC.

Methods: In this study, we will perform a comprehensive search strategy in the databases as follows: Cochrane Library, EMBASE, MEDLINE, PSYCYINFO, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data from inception to February 28, 2019. All case-controlled studies exploring the impacts of FFDM diagnosis for patients BC will be fully considered for inclusion in this study. Two authors will independently scan the title and abstracts for relevance, and assess full texts for inclusion. They will also independently extract data and will assess methodological quality for each included study by using Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool. RevMan V.5.3 software (London, UK) and Stata V.12.0 software (Texas, USA) will be used to pool the data and to conduct the meta-analysis.

Results: The sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of FFDM will be used to determine the diagnostic accuracy of FFDM for the diagnosis of patients with BC.

Conclusion: Its findings will provide latest evidence for the diagnostic accuracy of FFDM in female patients with BC.

Systematic review registration: PROSPERO CRD42019125338.

Abbreviations: BC = breast cancer, CI = confidence intervals, DCIS = ductal carcinoma in situ, FFDM = full field digital mammography, ILC = invasive lobular carcinoma, NST = invasive ductal carcinoma of no special type.

Keywords: breast cancer, full field digital mammography, sensitivity, specificity

1. Introduction

Breast cancer (BC) is the most common gynecological cancers among female population around the world.[1–3] It is also the most common cause of cancer death.[4–6] The incidence and mortality rates have increased yearly worldwide.[7–8] It has been estimated that about 63,960 cases were diagnosed and 266,120 deaths from BC worldwide.[9]

It has been found that mammography, such as full field digital mammography (FFDM) can greatly reflect the fibro-glandular tissue in a woman’s breast.[11–12] Thus, it is often used and is regarded as the gold standard imaging tool for BC screening among female population.[6,13,14] Numerous clinical studies have reported to use FFDM for BC diagnosis and have achieved very promising outcome results.[15–29] However, no study systematically has assessed its accuracy on patients with BC. Thus, in this study, we will systematically evaluate the diagnostic accuracy of FFDM for patients with BC.

2. Methods

2.1. Objective

This systematic review will aim to assess the value of FFDM in the diagnosis of female patients with BC.

2.2. Study registration

This study has been registered on PROSPERO CRD42019125338. It has been reported follow the guideline of Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) statement.[30]

2.3. Inclusion criteria for study selection

2.3.1. Type of studies.

This study will include case-controlled studies reporting the diagnostic accuracy of FFDM for the diagnosis of female patients with BC. However, we will exclude...
non-clinical studies, case report, case series, and non-controlled studies.

2.3.2. Type of participants. In this study, the reports of female patients with histologically proven BC will be fully considered for inclusion.

2.3.3. Type of index test. Index test: any forms of FFDM will be used to diagnose patients with BC. However, the combinations of FFMD with other diagnostic test will be excluded. Reference test: patients with histologically proven BC only will be considered in the control group.

2.3.4. Type of outcome measurements. The primary outcome measurements include sensitivity and specificity. The secondary outcome measurements consist of positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio.

2.4. Data sources and search strategy
2.4.1. Electronic searches. The electronic databases of Cochrane Library, EMBASE, MEDLINE, PsycINFO, Web of Science, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, VIP Information, and Wanfang Data will be searched from inception to February 28, 2019 without any language restrictions. The sample of search strategy for Cochrane Library is shown in Table 1. Identified search strategies will also applied to other electronic databases.

2.4.2. Other resources. Clinical registry and reference list of included studies and relevant reviews will also be searched.

2.5. Data collection and analysis
2.5.1. Selection of studies. Endnote 7.0 software (Philadelphia, PA) will be used to manage the literature search records and remove the duplicated studies. Two authors will independently scan titles and abstracts initially according to the prede
dined eligibility criteria. Then, they will read full texts to further judge if they can meet the final eligibility criteria. The process of study selection will follow the PRISMA-P guidelines, and will be shown in PRISMA flowchart. Any divergences between 2 authors will be settled down by a third author.

2.5.2. Data collection and management. Two authors will independently extract data by using pre-designed form for data extraction. Any disagreements regarding the data extraction between 2 authors will be solved by consulting a third author.

The following information will be collected and relevant data will be extracted, including study characteristics, such as title, authors, year of publication, country; patient characteristics, such as race, age, sex, inclusion and exclusion criteria; details of diagnostic methods; study method, such as randomization, blinding, and concealment; outcome measurements, such as the number of true positives and negatives, false positives and negatives for each diagnostic test from each included study performance $2 \times 2$ tables.

2.5.3. Dealing with missing data. If there are insufficient data, we will contact the primary authors to require those data. If those data are not achievable, we will only analyze the available data.

2.6. Methodological quality assessment
The methodological quality will be measured by Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool for each included study. This tool consists of 4 domains: patient selection, index test, reference standard, and flow and timing. Each domain is evaluated with risk of bias, which is judged by using signaling questions. The first 3 fields are also evaluated in terms of concerns regarding applicability. Two authors will independently assess the methodological quality for each study. Any disagreements will be resolved by discussion with a third author.

2.7. Statistical analysis
RevMan V.5.3 software and Stata V.12.0 software will be used to analyze the data and to carry out the meta-analysis. Data will be entered into Stata V.12.0 software and will plot estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio from the diagnostic $2 \times 2$ tables of primary studies. Descriptive statistics with 95% confidence intervals will be calculated for each primary study. Then, a descriptive forest plot will be derived. In addition, a summary receiver operating characteristic plot will also be performed.

2.7.1. Assessment of heterogeneity. The degree of statistical heterogeneity will be identified by measured $I^2$ statistic. If $I^2 \leq 50\%$, low heterogeneity is considered. Otherwise, if $I^2 > 50\%$, the significant heterogeneity will be regarded.

2.7.2. Data synthesis. If heterogeneity is low ($I^2 \leq 50\%$), data will be pooled, and meta-analysis will be conducted. If heterogeneity is significant ($I^2 > 50\%$), data will be pooled.

### Table 1

| Search terms |
|---------------|
| Number |
| Mesh descriptor: (breast neoplasms) explode all trees |
| Or 1–2 |
| MeSH descriptor: (mammography) explode all trees |
| Or 4–5 |
| MeSH descriptor: (case–control studies) explode all trees |
| Or 7–8 |

References: [31]
accordance to the results of subgroup analysis. If the heterogeneity is still significant after subgroup analysis, data will not be pooled, and meta-analysis will not be performed directly. However, a bivariate random‐effects regression approach will be utilized for summary of estimates of sensitivity and specificity.

2.7.3. **Subgroup analysis**. Subgroup analysis will be carried out to detect any causes that may result in significant heterogeneity according to the different study characteristics, and patient characteristics.

2.7.4. **Sensitivity analysis**. Sensitivity analysis will be conducted by eliminating the low methodological quality studies.

2.7.5. **Reporting bias**. We will carry out funnel plots and associated regression tests to check if there are any publication biases.

2.8. **Ethics and dissemination**

This study does not require research ethic, because it will not analyze individual patient data. The results of this study are expected to be published on peer-reviewed journals.

3. **Discussion**

This systematic review will first investigate the diagnostic accuracy of FFDM in female patients with BC by assessing the sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio. The results of this systematic review will provide a summary of the most recent evidence on the diagnostic accuracy of FFDM for BC. Its findings may also provide helpful evidence for the BC diagnosis and further researchers.

**Author contributions**

**Conceptualization**: Tuan Wang, Xing Li, Zhi Wen.

**Data curation**: Tuan Wang, Jian‐jun Shuai, Zhi Wen.

**Formal analysis**: Jian‐jun Shuai, Xing Li.

**Investigation**: Zhi Wen.

**Methodology**: Tuan Wang, Jian‐jun Shuai, Xing Li.

**Project administration**: Tuan Wang, Zhi Wen.

**Resources**: Tuan Wang, Jian‐jun Shuai, Xing Li.

**Software**: Tuan Wang, Jian‐jun Shuai, Xing Li.

**Supervision**: Zhi Wen.

**Validation**: Jian‐jun Shuai, Xing Li.

**Visualization**: Tuan Wang, Xing Li, Zhi Wen.

**Writing – original draft**: Tuan Wang, Jian‐jun Shuai, Xing Li, Zhi Wen.

**Writing – review & editing**: Tuan Wang, Jian‐jun Shuai, Xing Li, Zhi Wen.

**References**

[1] van Marecke C, Collard A, Våkelsø M, et al. Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: a systematic review and meta-analysis of gene panel data. Crit Rev Oncol Hematol 2018;132:138–44.

[2] Tosello G, Torloni MR, Mota BS, et al. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 2018;3:CD011276.

[3] Pears KS, Choi Y, Stewart RW, et al. Screening for breast cancer. Semin Oncol 2017;44:60–72.

[4] Vanderpuye V, Grover S, Hammad N, et al. An update on the management of breast cancer in Africa. Infect Agent Cancer 2017;12:13.

[5] Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol 2016;59:651–72.

[6] Fiorica JV. Breast cancer screening, mammography, and other modalities. Clin Obstet Gynecol 2016;59:688–709.

[7] Sprok I, Schellevis FG, Burgers JS, et al. Incidence of isolated local breast cancer recurrence and contralateral breast cancer: a systematic review. Breast 2018;39:70–9.

[8] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–386.

[9] Vavadi H, Mostafa A, Zhou F, et al. Compact ultrasound-guided diffuse optical tomography system for breast cancer imaging. J Biomed Opt 2018;24:1–9.

[10] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol 2014;15:e279–89.

[11] Bleyer A, Baines C, Miller AB. Impact of screening mammography on breast cancer mortality. Int J Cancer 2016;138:2003–12.

[12] Zhu C, Wang L, Du LB, et al. The accuracy of mammography screening for breast cancer: a meta-analysis. Zhonghua Liu Xing Bing Xue Za Zhi 2016;37:1296–305.

[13] Takahashi TA, Lee CI, Johnson KM. Breast cancer screening: does tomosynthesis augment mammography? Cleve Clin J Med 2017;84:522–7.

[14] Zhang Y, Ren H. Meta-analysis of diagnostic accuracy of magnetic resonance imaging and mammography for breast cancer. J Cancer Res Ther 2017;13:862–8.

[15] Lewin JM, D’Oros CJ, Hendrick RE, et al. Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. AJR Am J Roentgenol 2002;179:671–7.

[16] Sgouros BF. Screen-film versus full-field digital mammography: comparison in breast cancer screening. Acta Radiol 2005;46:663.

[17] Seo BK, Pisano ED, Kuzmaik CM, et al. The positive predictive value for diagnosis of breast cancer full-field digital mammography versus film-screen mammography in the diagnostic mammographic population. Acad Radiol 2006;13:1229–35.

[18] The JS, Schilling KJ, Hoffmeister JW, et al. Detection of breast cancer with full-field digital mammography and computer-aided detection. AJR Am J Roentgenol 2009;192:340–7.

[19] Pinker K, Perry N, Vinnicombe S, et al. Consistency of breast cancer according to histopathological type and breast density when imaged by full-field digital mammography compared with screen-film mammography. Eur Radiol 2011;21:18–25.

[20] Hoff SR, Abrahamsen AL, Samset JH, et al. Breast cancer: missed interval detection and screening-detected cancer at full-field digital mammography and screen-film mammography: results from a retrospective review. Radiol 2012;264:378–86.

[21] Thevi Rajendran P, Krishnapillai V, Tamanang S, et al. Comparison of image quality criteria between digital storage phosphor plate in mammography and full-field digital mammography in the detection of breast cancer. Malays J Med Sci 2012;19:52–9.

[22] Murakami R, Kumita S, Tani H, et al. Detection of breast cancer with a computer-aided detection applied to full-field digital mammography. J Digit Imaging 2013;26:768–73.

[23] Mun HS, Kim HH, Shin HJ, et al. Assessment of extent of breast cancer: comparison between digital breast tomosynthesis and full-field digital mammography. Clin Radiol 2013;68:1254–9.

[24] Park CS, Jung NY, Kim K, et al. Detection of breast cancer in asymptomatic and symptomatic groups using computer-aided detection. Breast 2016;37:1296–305.

[25] Roark AA, Dang PA, Niell BL, et al. Performance of screening breast MRI after negative full-field digital mammography versus after negative digital breast tomosynthesis in women at higher than average risk for breast cancer. AJR Am J Roentgenol 2019;212:271–9.
[29] van Nijnatten TJ, Smidt ML, Goorts B, et al. Can high school students help to improve breast radiologists in detecting missed breast cancer lesions on full-field digital mammography? J Cancer 2019;10:765–71.

[30] Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.

[31] Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:329–36.

[32] Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882–93.